Alessandra di Pietro
Pfizer (Italy)(IT)
Publications by Year
Research Areas
Renal cell carcinoma treatment, Bladder and Urothelial Cancer Treatments, Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, Urinary and Genital Oncology Studies
Most-Cited Works
- → Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma(2019)2,502 cited
- → Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma(2020)1,443 cited
- → Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial(2020)506 cited
- → Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma(2020)454 cited
- → Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial(2018)258 cited
- → Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer(2010)232 cited
- → Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up(2023)200 cited
- → COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients WithBRAFV600–Mutant Melanoma(2022)179 cited
- → Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach(2010)140 cited
- → Hormonal and reproductive factors in relation to melanoma in women: Current review and meta-analysis(2011)127 cited